specialized consultants to provide a feasibility review and develop a business plan for development of a viral vector manufacturing facility in a current cell manufacturing facility

SOL #: 26-002367Pre-Solicitation

Overview

Buyer

Health And Human Services
National Institutes Of Health
NATIONAL INSTITUTES OF HEALTH - CC
BETHESDA, MD, 20892, United States

Place of Performance

Bethesda, MD

NAICS

All Other Professional (541990)

PSC

Other Professional Services (R499)

Set Aside

No set aside specified

Timeline

1
Posted
Mar 4, 2026
2
Response Deadline
Mar 10, 2026, 4:00 PM

Qualification Details

Fit reasons
  • NAICS alignment with historical contract wins in similar service areas.
  • Scope strongly matches core technical capabilities and delivery model.
Risks
  • Past performance thresholds may require one additional teaming partner.
  • Potential clarification needed on staffing minimums before bid/no-bid.
Next steps

Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.

Quick Summary

The National Institutes of Health (NIH), Clinical Center has issued a Notice of Intent (NOI) to procure specialized consultants for a feasibility review and business plan development for a viral vector manufacturing facility in Bethesda, MD. This facility will support Phase I and early Phase II studies at the NIH Clinical Center, focusing on retroviral/lentiviral vectors, AAV, and future nanoparticles. This is not a request for quotation, and a solicitation will not be issued.

Scope of Work

The selected consultants will provide:

  • A comprehensive feasibility review for establishing a viral vector manufacturing facility.
  • Development of a detailed business plan for the facility.
  • Focus on manufacturing retroviral/lentiviral vectors, AAV, and transitioning to future nanoparticles.
  • Support for Phase I and early Phase II studies conducted at the NIH Clinical Center.

Contract & Timeline

  • Type: Notice of Intent (NOI) for a single-source acquisition.
  • Acquisition Method: Federal Acquisition Regulation (FAR) Part 13 – Simplified Acquisition Procedures, Subpart 13.106-1(b)(1), allowing for solicitation from one source if deemed reasonably available. This acquisition is exempt from FAR Part 6 – Competition Requirements.
  • Set-Aside: None specified.
  • Response Due: March 10, 2026, by 4:00 PM ET.
  • Published: March 4, 2026.
  • Place of Performance: Bethesda, MD.

Response & Government Discretion

Interested parties may identify their interest and capabilities in response to this posting. The Government's determination not to compete the proposed requirement, based on responses to this notice, is solely within its discretion.

Additional Notes

Comments referencing this posting number should be submitted to Susan Nsangou, Contracting Officer, via email at susan.nsangou@nih.gov by the closing date.

People

Points of Contact

Susan NsangouPRIMARY

Files

Files

No files attached to this opportunity

Versions

Version 1Viewing
Pre-Solicitation
Posted: Mar 4, 2026
specialized consultants to provide a feasibility review and develop a business plan for development of a viral vector manufacturing facility in a current cell manufacturing facility | GovScope